Starpharma Holdings Limited (PQ6)

Overview

Starpharma Holdings Limited, established in 1997, is an innovative biopharmaceutical company based in Abbotsford, Australia. It specializes in the research, development, and commercialization of dendrimer products, which are utilized across various applications in the pharmaceutical and life-sciences sectors globally. The company focuses on creating and offering advanced therapies and preventative treatments for a range of conditions, leveraging dendrimer technology to improve delivery, efficacy, and safety of drugs. It is actively involved in clinical trials to push the boundaries of cancer treatment and infectious disease prevention.

Products and Services

VivaGel BV: This non-antibiotic vaginal gel is designed for the treatment of bacterial vaginosis (BV) and the prevention of its recurrence. It offers a novel approach to managing this common vaginal condition without the use of traditional antibiotics.

VIRALEZE: An antiviral nasal spray developed as a preventative measure against viral infections. Its easy application and mechanism of action aim to provide a barrier to viruses, potentially reducing the incidence and spread of viral diseases.

VivaGel Condom: This product incorporates the company's proprietary VivaGel technology into condoms to provide an antiviral barrier, designed to reduce the transmission of sexually transmitted infections (STIs), including HIV and herpes simplex virus (HSV).

DEP Cabazitaxel: Currently in Phase 2 clinical trials, this treatment is being investigated for its effectiveness against prostate and other cancers. It represents the company's dedication to advancing cancer treatment through its DEP drug delivery platform.

DEP Docetaxel: Also in Phase 2 clinical trials, DEP Docetaxel is under investigation for the treatment of colorectal and other cancers, utilizing the DEP technology to potentially improve outcomes for cancer patients.

DEP Irinotecan: This product is in Phase 2 clinical trials for the treatment of pancreatic and other cancers, showcasing Starpharma's commitment to expanding its oncology portfolio with novel therapeutics.

DEP Radiotheranostics Development Pipeline: The company's pipeline includes innovative treatments like DEP HER2-zirconium, a HER2-targeted radiodiagnostic for HER2-positive cancers such as breast and gastric cancer, and the HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. These developments indicate Starpharma's efforts in exploring and delivering cutting-edge solutions in cancer diagnostics and therapy.